35.22

8.20% 2.67

After Hours: 35.43 0.21 +0.60%

Stoke Therapeutics Inc (STOK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Stoke Therapeutics Inc stock is traded at $35.22, with a volume of 1.12M. It is up +8.20% in the last 24 hours and up +14.09% over the past month. Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Previous Close:

$32.55

Open:

$32.22

24h Volume:

1.12M

Relative Volume:

1.02

Market Cap:

$2.01B

Revenue:

$199.89M

Net Income/Loss:

$52.48M

P/E Ratio:

41.44

EPS:

0.85

Net Cash Flow:

$61.15M

1W Performance:

+10.69%

1M Performance:

+14.09%

6M Performance:

+206.79%

1Y Performance:

+219.60%

1-Day Range:

$32.22

$35.74

1-Week Range:

$29.75

$35.74

52-Week Range:

$5.35

$38.69

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name

Stoke Therapeutics Inc

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

781-430-8200

Address

45 WIGGINS AVENUE, BEDFORD, MA

Employee

128

Twitter

@stoketx

Next Earnings Date

2025-03-18

Latest SEC Filings

STOK's Discussions on Twitter

Compare STOK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STOK Stoke Therapeutics Inc	35.22	1.86B	199.89M	52.48M	61.15M	0.85
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-18-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Chardan Capital Markets	Buy
Oct-14-24	Resumed	Leerink Partners	Outperform
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral
Apr-26-23	Resumed	Canaccord Genuity	Buy
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-31-22	Initiated	Jefferies	Buy
Dec-03-21	Initiated	BofA Securities	Buy
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight
May-18-21	Initiated	UBS	Neutral
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy
Dec-11-20	Reiterated	Needham	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-29-20	Resumed	JP Morgan	Neutral
Sep-29-20	Initiated	Needham	Buy
Dec-18-19	Initiated	Wedbush	Outperform
Nov-12-19	Initiated	BTIG Research	Buy
Oct-25-19	Initiated	H.C. Wainwright	Buy
Jul-15-19	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Credit Suisse	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight

View All

Stoke Therapeutics Inc Stock (STOK) Latest News

Jan 05, 2026

Stoke Therapeutics (STOK): New Analyst Price Target Raises to $3 - GuruFocus

Jan 05, 2026

Cantor Fitzgerald reiterates Overweight rating on Stoke Therapeutics stock By Investing.com - Investing.com UK

Jan 05, 2026

Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital - MarketBeat

Jan 05, 2026

Analyst Raises Price Target for STOK: Stoke Therapeutics | STOK Stock News - GuruFocus

Jan 05, 2026

Chardan Capital Markets assumes coverage on Stoke Therapeutics stock with Buy rating - Investing.com Canada

Jan 05, 2026

Jan 04, 2026

Discipline and Rules-Based Execution in STOK Response - Stock Traders Daily

Jan 04, 2026

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - MSN

Jan 04, 2026

Dec 29, 2025

Stoke Therapeutics (NASDAQ:STOK) shareholders are still up 246% over 3 years despite pulling back 4.8% in the past week - Yahoo Finance

Dec 29, 2025

Dec 24, 2025

(STOK) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Dec 24, 2025

Dec 23, 2025

BTIG Reiterates Stoke Therapeutics (STOK) Buy Recommendation - MSN

Dec 23, 2025

Stoke Therapeutics (STU:0GT) EV-to-OCF : 25.98 (As of Dec. 23, 2025) - GuruFocus

Dec 23, 2025

Dec 22, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Dec 22, 2025

Dec 20, 2025

Inflation Data: Is Stoke Therapeutics Inc. stock a buy in volatile marketsRate Hike & Weekly Consistent Profit Watchlists - Улправда

Dec 20, 2025

Aug Swings: What valuation multiples suggest for Stoke Therapeutics Inc stockQuarterly Portfolio Summary & Technical Buy Zone Confirmation - moha.gov.vn

Dec 20, 2025

Corient Private Wealth LLC Invests $7.49 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat

Dec 20, 2025

Assenagon Asset Management S.A. Has $21.16 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat

Dec 20, 2025

Is Stoke Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Recap & Verified Momentum Stock Watchlist - Улправда

Dec 20, 2025

Dec 19, 2025

Stoke Therapeutics (FRA:0GT) EV-to-OCF : 25.91 (As of Dec. 19, 2025) - GuruFocus

Dec 19, 2025

Dec 18, 2025

Analyst Confidence Surges for Stoke Therapeutics Following Key Data - AD HOC NEWS

Dec 18, 2025

Dec 17, 2025

Equities Analysts Set Expectations for STOK FY2027 Earnings - MarketBeat

Dec 17, 2025

Dec 16, 2025

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com

Dec 16, 2025

Biotech leader Stoke Therapeutics offers multiple entries as revenue surges 117% - MSN

Dec 16, 2025

Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright By Investing.com - Investing.com South Africa

Dec 16, 2025

Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright - Investing.com Nigeria

Dec 16, 2025

Dec 15, 2025

HC Wainwright & Co. Maintains Stoke Therapeutics (STOK) Buy Recommendation - Nasdaq

Dec 15, 2025

Stoke Therapeutics Inc diskutieren - sharewise.com

Dec 15, 2025

Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $50.00 at HC Wainwright - MarketBeat

Dec 15, 2025

STOK: HC Wainwright & Co. Raises Price Target to $50 | STOK Stoc - GuruFocus

Dec 15, 2025

Dec 13, 2025

(STOK) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com

Dec 13, 2025

Stoke Therapeutics: A Deep Dive into Clinical Progress and Market Sentiment - AD HOC NEWS

Dec 13, 2025

Dec 12, 2025

Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? - AOL.com

Dec 12, 2025

Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat

Dec 12, 2025

Dec 11, 2025

Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 3,978 Shares of Stock - MarketBeat

Dec 11, 2025

Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock - MarketBeat

Dec 11, 2025

Dec 10, 2025

Insider Selling Alert: Kaye Edward M. MD Sells Shares of Stoke T - GuruFocus

Dec 10, 2025

Stoke Therapeutics Insider Sold Shares Worth $433,385, According to a Recent SEC Filing - marketscreener.com

Dec 10, 2025

Dir Kaye Sells 13,430 ($433.4K) Of Stoke Therapeutics Inc [STOK] - TradingView — Track All Markets

Dec 10, 2025

Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4%Time to Buy? - MarketBeat

Dec 10, 2025

Dec 09, 2025

After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq

Dec 09, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Dec 09, 2025

Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.1%What's Next? - MarketBeat

Dec 09, 2025

Marshall Wace LLP Acquires 168,771 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat

Dec 09, 2025

STOK Crosses Above Average Analyst Target - Nasdaq

Dec 09, 2025

Dec 08, 2025

Officer Allan Files To Sell 3,978 Of Stoke Therapeutics Inc [STOK] - TradingView — Track All Markets

Dec 08, 2025

With Stoke Therapeutics Stock Surging, Have You Considered The Downside? - Trefis

Dec 08, 2025

Dec 07, 2025

Stoke Therapeutics highlights Zorevunersen’s potential at epilepsy meeting - MSN

Dec 07, 2025

Biogen, Stoke Therapeutics announce data presentations for zorevunersen - MSN

Dec 07, 2025